Serotonin receptors in cognitive behaviors

doi:10.1016/S0959-4388(97)80013-X

Current Opinion in Neurobiology

Volume 7, Issue 2, April 1997, Pages 243-254

https://doi.org/10.1016/S0959-4388(97)80013-X Get rights and content

Abstract

The serotonergic system appears to play a role in behaviors that involve a high cognitive demand and in memory improvement or recovery from impaired cognitive performance, as made evidence after administration of serotonin 5-HT_2A/5-HT_2C or 5-HT₄ receptor agonists or 5-HT_1A or 5-HT₃ receptor antagonists. These serotonin receptor subtypes are localized on ‘cognitive’ pathways, with the hippocampus and frontal cortex as the main target structures. A better understanding of the role played by these and other serotonin receptor subtypes in cognition is likely to result from the recent availability of new specific ligands and new molecular tools, such as gene knock-out and transgenic mice.

References (67)

J-C Cassel et al.
Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications
Neuroscience
(1995)
J Sirviö et al.
Experimental studies on the role of serotonin in cognition
Prog Neurobiol
(1994)
S Lister et al.
Acquisition of conditioned inhibition in rats is impaired by ablation of serotoninergic pathways
Eur J Neurosci
(1996)
AHJ Herremans et al.
Serotonergic drug effects on a delayed conditional discrimination task in the rat: involvement of the 5-HT_1A receptor in working memory
J Psychopharmacol
(1995)
GJ Kant et al.
Effects of the serotonin receptor agonists 8-OH-DPAT and TFMPP on learning as assessed using a novel water maze
Pharmacol Biochem Behav
(1996)
HK Kia et al.
Serotonin1A receptors are expressed by a subpopulation of cholinergic neurons in the rat medial septum and diagonal band of Broca — a double immunocytochemical study
Neuroscience
(1996)
M Skingle et al.
GR127935: a potent and selective 5-HT_1D receptor antagonist
Behav Brain Res
(1996)
GE Torres et al.
Cyclic AMP protein kinase A mediate 5-hydroxytryptamine type 4 receptor regulation of calcium-activated potassium current in hippocampal neurons
Mol Pharmacol
(1995)
H Ansanay et al.
cAMP-dependent, long-lasting inhibition of a K⁺ current in mammalian neurons
Proc Natl Acad Sci USA
(1995)
DJ Fontana et al.
Stereoselective effects of (R)- and (S)-zacopride on cognitive performance in a spatial navigation task in rats
Neuropharmacology
(1996)

JM Barnes et al.

The effects of ondansetron, a 5-HT₃ receptor antagonist, on cognition in rodents and primates

Pharmacol Biochem Behav

(1990)

U Staubli et al.

Effects of 5-HT-sub-3 receptor antagonism on hippocampal theta rhythm, memory, and LTP induction in the freely moving rat

J Neurosci

(1995)

M Morales et al.

Cellular and subcellular immunolocalization of the type 3 serotonin receptor in the rat central nervous system

Mol Brain Res

(1996)

MJ Ramirez et al.

Involvement of GABA systems in acetylcholine release induced by 5-HT₃ receptor blockade in slices from rat entorhinal cortex

Brain Res

(1996)

P Jäkälä et al.

The effects of p-chlorophenylalanine-induced serotonin synthesis inhibition and muscarinic blockade on the performance of rats in a 5-choice serial reaction time task

Behav Brain Res

(1992)

JL Muir et al.

Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT₃ receptor antagonist, ondansetron

Psychopharmacology

(1995)

TA Sipes et al.

8-OH-DPAT disruption of prepulse inhibition in rats: reversal with (+)WAY 100, 135 and localization of site of action

Psychopharmacology

(1995)

FG Graeff et al.

Opposed regulation by dorsal raphe nucleus 5-HT pathways of two types of fear in the elevated T-maze

Pharmacol Biochem Behav

(1996)

T Inoue et al.

Serotonin activation reduces defensive freezing in the conditioned fear paradigm

Pharmacol Biochem Behav

(1996)

SF Maier et al.

8-OH-DPAT microinjected in the region of the dorsal raphe nucleus blocks and reverses the enhancement of fear-conditioning and interference with escape produced by exposure to inescapable shock

Behav Neurosci

(1995)

M Mayford et al.

Control of memory formation through regulated expression of a CaMKII transgene

Science

(1996)

T Steckler et al.

The role of serotonergic—cholinergic interactions in the mediation of cognitive behaviour

Behav Brain Res

(1995)

SSA Al-Zahrani et al.

Effect of destruction of the 5-hydroxytryptaminergic pathways on the acquisition of temporal discrimination and memory for duration in a delayed conditional discrimination task

Psychopharmacology

(1996)

AC Santucci et al.

Excessive serotonin release, not depletion, leads to memory impairments in rats

Eur J Pharmacol

(1996)

A Menenes et al.

Effect of fluoxetine on learning and memory involves multiple 5-HT systems

Pharmacol Biochem Behav

(1995)

D Hoyer et al.

Classification and nomenclature of 5-HT receptors: a comment on current issues

Behav Brain Res

(1996)

M Carli et al.

8-OH-DPAT impairs spatial but not visual learning in a water maze by stimulating 5-HT_1A receptors in the hippocampus

Behav Brain Res

(1995)

M Carli et al.

(S)-WAY 100135, a 5-HT_1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine

Eur J Pharmacol

(1995)

A Fletcher et al.

Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT_1A receptor antagonist

Behav Brain Res

(1996)

JA Harder et al.

The 5-HT_1A antagonist. WAY 100635, ameliorates the cognitive impairment induced by formix transection in the marmoset

Psychopharmacology

(1996)

M Riekkinen et al.

Combined treatment with a 5-HT_1A receptor agonist and a muscarinic acetylcholine receptor antagonist disrupts water maze navigation behavior

Psychopharmacology

(1995)

GG Kinney et al.

Medial septal unit firing characteristics following injections of 8-OH-DPAT into the median raphe nucleus

Brain Res

(1996)

D Schmitz et al.

Serotonin reduce inhibition via 5-HT_1A receptors in area CA1 of rat hippocampal slices in vitro

J Neurosci

(1995)

Cited by (280)

Fluoxetine may interfere with learning in fish
2024, Environmental Toxicology and Pharmacology
Our study aimed to test whether fluoxetine impairs learning in fish and whether this potential impairment is reversible. Learning efficiency, with no aversive stimuli, of the Carassius carassius was analysed under different pharmaceutical conditions: (i) fish cultured without antidepressant (control), (ii) fish exposed to fluoxetine for 21 days (fluoxetine), and (iii) fish exposed to fluoxetine for 21 days and then cultured without fluoxetine for another 21 days (recovery). We exposed animals to environmental concentrations (360 ng L⁻¹) of antidepressant. The learning rate was measured by timing how long it took the individual fish to find food and start feeding, six days in a row. The control and recovery fish took significantly less time to start eating over the six days. Control fish start eating 14 times faster than the fluoxetine fish. Fluoxetine can significantly affect learning and 21-day recovery period is not enough to fully restore the original learning abilities.
Interleukin-15 alters hippocampal synaptic transmission and impairs episodic memory formation in mice
2024, Brain, Behavior, and Immunity
Cytokines are potent immunomodulators exerting pleiotropic effects in the central nervous system (CNS). They influence neuronal functions and circuit activities with effects on memory processes and behaviors. Here, we unravel a neuromodulatory activity of interleukin-15 (IL-15) in mouse brain. Acute exposure of hippocampal slices to IL-15 enhances gamma-aminobutyric acid (GABA) release and reduces glutamatergic currents, while chronic treatment with IL-15 increases the frequency of hippocampal miniature inhibitory synaptic transmission and impairs memory formation in the novel object recognition (NOR) test. Moreover, we describe that serotonin is involved in mediating the hippocampal effects of IL-15, because a selective 5-HT₃A receptor antagonist prevents the effects on inhibitory neurotransmission and ameliorates mice performance in the NOR test. These findings provide new insights into the modulatory activities of cytokines in the CNS, with implications on behavior.
Stable in-vivo electrochemical sensing of tonic serotonin levels using PEDOT/CNT-coated glassy carbon flexible microelectrode arrays.
2023, Biosensors and Bioelectronics
Chronic sampling of tonic serotonin (5-hydroxytryptamine, 5-HT) concentrations in the brain is critical for tracking neurological disease development and the time course of pharmacological treatments. Despite their value, in vivo chronic multi-site measurements of tonic 5-HT have not been reported. To fill this technological gap, we batch-fabricated implantable glassy carbon (GC) microelectrode arrays (MEAs) onto a flexible SU-8 substrate to provide an electrochemically stable and biocompatible device/tissue interface. To achieve detection of tonic 5-HT concentrations, we applied a poly(3,4-ethylenedioxythiophene)/carbon nanotube (PEDOT/CNT) electrode coating and optimized a square wave voltammetry (SWV) waveform for selective 5-HT measurement. In vitro, the PEDOT/CNT-coated GC microelectrodes achieved high sensitivity to 5-HT, good fouling resistance, and excellent selectivity against the most common neurochemical interferents. In vivo, our PEDOT/CNT-coated GC MEAs successfully detected basal 5-HT concentrations at different locations within the CA2 region of the hippocampus of both anesthetized and awake mice. Furthermore, the PEDOT/CNT-coated MEAs were able to detect tonic 5-HT in the mouse hippocampus for one week after implantation. Histology reveals that the flexible GC MEA implants caused less tissue damage and reduced inflammatory response in the hippocampus compared to commercially available stiff silicon probes. To the best of our knowledge, this PEDOT/CNT-coated GC MEA is the first implantable, flexible sensor capable of chronic in vivo multi-site sensing of tonic 5-HT.
Using type-2 fuzzy ontology to improve semantic interoperability for healthcare and diagnosis of depression
2023, Artificial Intelligence in Medicine
Ontology enhances semantic interoperability through integrating health data from heterogeneous sources and sharing information in a meaningful way. In the field of smart health services, semantic interoperability means the exchange and interpretation of data without ambiguity and uncertainty. However, existing classical ontologies are not able to represent vague and uncertain knowledge, especially in contexts of mental health disorders which are associated with varying degrees of uncertainty and inaccuracy of diagnosis, and in this case, the treatment is a complex and common mental process necessitating to share information accurately and unambiguously. Type-2 fuzzy set theory can offer a fruitful solution in order to control uncertainty or express ambiguous concepts in a dynamic and complex environment such as healthcare systems. Herein, a semantic framework for healthcare, and also monitoring mental health disorders using type-2 fuzzy set theory based on the Internet of Thing (IoT) is suggested, in which all depression-related concepts are semantically annotated to share detailed information with the treatment staff. This framework not only paved the way to increasing the accuracy of medical diagnosis and decision-making but also provides the possibility of inference and semantic reasoning using the languages of SPARQL query and DL query.
Fenfluramine modulates the anti-amnesic effects induced by sigma-1 receptor agonists and neuro(active)steroids in vivo
2022, Epilepsy and Behavior
Citation Excerpt :
We used the anti-amnesic effect on dizocilpine-induced memory impairment in mice as it is historically a very pertinent in vivo model for the analysis of drug activity for S1R agonists [20,23,29,30,37,41–43] and S1R-positive modulators [31]. The test is also pertinent for the analysis of serotoninergic drugs [40,44,45]. Pharmacological activities could be differentiated, based on selective antagonists for S1R or subtypes of 5-HT receptors.
Fenfluramine (N-ethyl-α-methl-3-(trifluoromethyl)phenethylamine) is an anti-seizure medication (ASM) particularly effective in patients with Dravet syndrome, a severe treatment-resistant epileptic encephalopathy. Fenfluramine acts not only as neuronal serotonin (5-HT) releaser but also as a positive modulator of the sigma-1 receptor (S1R). We here examined the modulatory activity of Fenfluramine on the S1R-mediated anti-amnesic response in mice using combination analyses. Fenfluramine and Norfenfluramine, racemate and isomers, were combined with either the S1R agonist (PRE-084) or the S1R-acting neuro(active)steroids, pregnenolone sulfate (PREGS), Dehydroepiandrosterone sulfate (DHEAS), or progesterone. We report that Fenfluramine racemate or (+)-Fenfluramine, in the 0.1–1 mg/kg dose range, attenuated the dizocilpine-induced learning deficits in spontaneous alternation and passive avoidance, and showed low-dose synergies in combination with PRE-084. These effects were blocked by the S1R antagonist NE-100. Dehydroepiandrosterone sulfate or PREGS attenuated dizocilpine-induced learning deficits in the 5–20 mg/kg dose range. Co-treatments at low dose between steroids and Fenfluramine or (+)-Fenfluramine were synergistic. Progesterone blocked Fenfluramine effect. Finally, Fenfluramine and (+)-Fenfluramine effects were prevented by the 5-HT_1A receptor antagonist WAY-100635 or 5-HT_2A antagonist RS-127445, but not by the 5-HT_1B/1D antagonist GR 127935 or the 5-HT_2C antagonist SB 242084, confirming a 5-HT_1A and 5-HT_2A receptor involvement in the drug effect on memory. We therefore confirmed the positive modulation of Fenfluramine racemate or dextroisomer on S1R and showed that, in physiological conditions, the drug potentiated the low dose effects of neuro(active)steroids, endogenous S1R modulators. The latter are potent modulators of the excitatory/inhibitory balance in the brain, and their levels must be considered in the antiepileptic action of Fenfluramine.
4-Nonylphenol and 4-tert-octylphenol induce anxiety-related behaviors through alternation of 5-HT receptors and transporters in the prefrontal cortex
2020, Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology
Environmental endocrine disruptors 4-nonylphenol (NP) and 4-tert-octylphenol (OP) may cast huge harm to human health. We used a rat model to observe the influence of NP or/and OP exposure on anxiety-related behaviors and the underlying mechanisms. Eighty male Sprague-Dawley (SD) rats were randomly divided into 10 groups: control group (corn oil), NP groups [30, 90, 270 mg/kg], OP groups [40, 120, 360 mg/kg] and NO groups [(mixed with the corresponding NP, OP alone exposed low, medium and high dose according to the natural environment exists NP:OP = 4:1]. The rats were orally administered every other day for 30 days. The neurobehaviors of rats were evaluated by open-field test (OFT) and elevated plus-maze test (EPM), and the concentrations of 5-HT, monoamine oxidase (MAOA), serotonin transporter (SERT), vesicular monoamine transporter 2 (VAMT2), 5-hydroxytryptamine 1A (5-HT_1A), 5-hydroxytryptamine 2A (5-HT_2A)，and 5-hydroxytryptamine 2C (5-HT_2C) in the rat prefrontal cortex were analyzed by ELISA. OFT and EPM tests showed that NP or/and OP exposure induced anxiety-related behaviors in rats. 5-HT levels were significantly increased compared with the control group. The levels of MAOA, SERT, VAMT2, 5-HT_1A, 5-HT_2A, and 5-HT_2C in the prefrontal cortex reduced in different degrees by high-doses NP or/and OP exposure. In summary, NP or/and OP exposure might cause anxiety-related behaviors in rats through regulating neurotransmitter 5-HT levels by altering the expression of 5-HT decomposition enzyme MAOA, transporters SERT and VMAT2, and 5-HT receptors 5-HT_1A, 5-HT_2A, and 5-HT_2C.

View all citing articles on Scopus

View full text

Serotonin receptors in cognitive behaviors

Abstract

Neuroscience

Prog Neurobiol

Eur J Neurosci

J Psychopharmacol

Pharmacol Biochem Behav

Neuroscience

Behav Brain Res

Mol Pharmacol

Proc Natl Acad Sci USA

Neuropharmacology

Pharmacol Biochem Behav

J Neurosci

Mol Brain Res

Brain Res

Behav Brain Res

Psychopharmacology

Psychopharmacology

Pharmacol Biochem Behav

Pharmacol Biochem Behav

Behav Neurosci

Science

The role of serotonergic—cholinergic interactions in the mediation of cognitive behaviour

Behav Brain Res

Effect of destruction of the 5-hydroxytryptaminergic pathways on the acquisition of temporal discrimination and memory for duration in a delayed conditional discrimination task

Psychopharmacology

Excessive serotonin release, not depletion, leads to memory impairments in rats

Eur J Pharmacol

Effect of fluoxetine on learning and memory involves multiple 5-HT systems

Pharmacol Biochem Behav

Classification and nomenclature of 5-HT receptors: a comment on current issues

Behav Brain Res

8-OH-DPAT impairs spatial but not visual learning in a water maze by stimulating 5-HT1A receptors in the hippocampus

Behav Brain Res

(S)-WAY 100135, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine

Eur J Pharmacol

Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist

Behav Brain Res

The 5-HT1A antagonist. WAY 100635, ameliorates the cognitive impairment induced by formix transection in the marmoset

Psychopharmacology

Combined treatment with a 5-HT1A receptor agonist and a muscarinic acetylcholine receptor antagonist disrupts water maze navigation behavior

Psychopharmacology

Medial septal unit firing characteristics following injections of 8-OH-DPAT into the median raphe nucleus

Brain Res

Serotonin reduce inhibition via 5-HT1A receptors in area CA1 of rat hippocampal slices in vitro

J Neurosci

8-OH-DPAT impairs spatial but not visual learning in a water maze by stimulating 5-HT_1A receptors in the hippocampus

(S)-WAY 100135, a 5-HT_1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine

Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT_1A receptor antagonist

The 5-HT_1A antagonist. WAY 100635, ameliorates the cognitive impairment induced by formix transection in the marmoset

Combined treatment with a 5-HT_1A receptor agonist and a muscarinic acetylcholine receptor antagonist disrupts water maze navigation behavior

Serotonin reduce inhibition via 5-HT_1A receptors in area CA1 of rat hippocampal slices in vitro